Regenxbio Q2 EPS $(1.66) Misses $(1.26) Estimate, Sales $19.98M Miss $39.83M Estimate
Portfolio Pulse from mahesh@benzinga.com
Regenxbio reported Q2 losses of $1.66 per share, missing the analyst consensus estimate of $1.26 by 31.75%. This is a 5.06% decrease from the same period last year. The company also reported quarterly sales of $19.98 million, missing the analyst consensus estimate of $39.83 million by 49.84%. This is a 38.81% decrease from the same period last year.
August 04, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Regenxbio's Q2 results missed estimates, with a larger than expected loss per share and lower sales. This could negatively impact the company's stock price in the short term.
Regenxbio's Q2 results were below expectations, with a larger loss per share and lower sales than anticipated. This could lead to a decrease in investor confidence and a potential drop in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100